Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO5072759 monotherapy versus rituximab in relapsed CD20-positive indolent non-Hodgkin lymphoma
2008-003460-19Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of obinutuzumab in non-Hodgkin lymphoma (NHL) and indolent lymphoma (2 arms), sponsored by Roche. Primary endpoints: overall response rate, safety and 1 more. Started Mar 2009; status: completed.
02
Drugs
obinutuzumab
03
Conditions
non-Hodgkin lymphoma (NHL)indolent lymphoma
Beyond the preview
Go deeper on 2008-003460-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003460-19.